S47. ADD-ON SPIRONOLACTONE FOR THE TREATMENT OF SCHIZOPHRENIA (SPIRO TREAT)

ABSTRACT: Abstract

Background

Patients with schizophrenia often display three main types of symptoms: positive symptoms (e.g. auditory hallucinations or delusions), negative symptoms (e.g. blunted affect, lack or decline in speech, social withdrawal) and cognitive symptoms (e.g. impairment of working memory and declarative memory). Treatment of positive symptoms with available antipsychotics is well established, while therapy options for cognitive and negative symptoms are lacking. Neurobiological studies identified an enhanced NRG1-ERBB4 signaling as a risk pathway in schizophrenia. Spironolactone was found to function as an inhibitor of the ERBB4 receptor. In Nrg1 type III transgenic mice, spironolactone treatment led to an improvement of schizophrenia-like symptoms (Wehr et al. 2017). Th

SUBMITTER: Roeh A 

PROVIDER: S-EPMC5888902 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature